In the last three months, 11 analysts have published ratings on RxSight RXST, offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings ...

New York State Common Retirement Fund lifted its position in RxSight, Inc. (NASDAQ:RXST – Free Report) by 32.6% during the fourth quarter, according to its most recent 13F filing with the SEC.

My name is Nasrin and I will be your conference operator today. At this time, I would like to welcome everyone to RxSight's Fourth Quarter 2024 Earnings Conference Call. [Operator Instructions] I ...

ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract ...

BTIG lowered the firm’s price target on RxSight (RXST) to $44 from $58 and keeps a Buy rating on the shares after its in-line Q4 results. The firm notes that the critical question for FY25 is ...

Shares of RXST opened at $28.36 on Wednesday. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -34.17 and a beta of 1.19. RxSight has a fifty-two week low of $26.29 and a ...

Last week, you might have seen that RxSight, Inc. ( NASDAQ:RXST ) released its annual result to the market. The early... RxSight ( NASDAQ:RXST ) Full Year 2024 Results Key Financial Results ...

My name is Desiree. And I will be your conference operator today. At this time, I would like to welcome everyone to our Rxsight fourth quarter 2024 earnings conference call. (Operator Instructions ...

ALISO VIEJO, California - RxSight, Inc. (NASDAQ:RXST) saw its shares surge 4.9% after the ophthalmic medical device company reported better-than-expected fourth quarter earnings and reaffirmed ...

Rxsight Inc. reported its fourth-quarter 2024 earnings, showcasing a notable earnings per share (EPS) performance with an actual EPS of $0.03, surpassing the forecasted EPS of -$0.17. The company ...